Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emmanuel Itti

Showing results (131-140 of 147) with videos related to

Pageof 15
Sort By:
Bulletin Du Cancer|January 27, 2019
[Update of the recommendations of good clinical practice for the use of PET in oncology]Pierre-Yves Salaün, Ronan Abgral, Olivier Malard, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 23, 2019
Good clinical practice recommendations for the use of PET/CT in oncologyPierre-Yves Salaün, Ronan Abgral, Olivier Malard, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|February 4, 2022
Describing mode of death in three major cardiac amyloidosis subtypes to improve management and survivalMounira Kharoubi, Diane Bodez, Mélanie Bézard, et al.
Hemasphere|January 14, 2022
Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell LymphomaRoch Houot, Viola Poeschel, Bettina Altmann, et al.
Blood Advances|January 9, 2026
Health-related quality of life after second-line Axi-cel in transplant-ineligible patients with large B-cell lymphomaEmilie Charton, Amélie Anota, Emmannuel Bachy, et al.
Haematologica|October 20, 2022
Prognostic value of positron emission tomography/computed tomography in transplant-eligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET studyFrançoise Kraeber-Bodéré, Sonja Zweegman, Aurore Perrot, et al.
Frontiers in Cardiovascular Medicine|March 31, 2023
Amylo-AFFECT-QOL, a self-reported questionnaire to assess health-related quality of life and to determine the prognosis in cardiac amyloidosisMounira Kharoubi, Mélanie Bézard, Amaury Broussier, et al.
Nature Medicine|October 9, 2023
Publisher Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trialRoch Houot, Emmanuel Bachy, Guillaume Cartron, et al.
Nature Medicine|May 14, 2024
Author Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trialRoch Houot, Emmanuel Bachy, Guillaume Cartron, et al.
Nature Medicine|September 14, 2023
Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trialRoch Houot, Emmanuel Bachy, Guillaume Cartron, et al.
Pageof 15

Showing results (131-140 of 147) with videos related to

Sort By:
Pageof 15
Bulletin Du Cancer|January 27, 2019
[Update of the recommendations of good clinical practice for the use of PET in oncology]Pierre-Yves Salaün, Ronan Abgral, Olivier Malard, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 23, 2019
Good clinical practice recommendations for the use of PET/CT in oncologyPierre-Yves Salaün, Ronan Abgral, Olivier Malard, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|February 4, 2022
Describing mode of death in three major cardiac amyloidosis subtypes to improve management and survivalMounira Kharoubi, Diane Bodez, Mélanie Bézard, et al.
Hemasphere|January 14, 2022
Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell LymphomaRoch Houot, Viola Poeschel, Bettina Altmann, et al.
Blood Advances|January 9, 2026
Health-related quality of life after second-line Axi-cel in transplant-ineligible patients with large B-cell lymphomaEmilie Charton, Amélie Anota, Emmannuel Bachy, et al.
Haematologica|October 20, 2022
Prognostic value of positron emission tomography/computed tomography in transplant-eligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET studyFrançoise Kraeber-Bodéré, Sonja Zweegman, Aurore Perrot, et al.
Frontiers in Cardiovascular Medicine|March 31, 2023
Amylo-AFFECT-QOL, a self-reported questionnaire to assess health-related quality of life and to determine the prognosis in cardiac amyloidosisMounira Kharoubi, Mélanie Bézard, Amaury Broussier, et al.
Nature Medicine|October 9, 2023
Publisher Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trialRoch Houot, Emmanuel Bachy, Guillaume Cartron, et al.
Nature Medicine|May 14, 2024
Author Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trialRoch Houot, Emmanuel Bachy, Guillaume Cartron, et al.
Nature Medicine|September 14, 2023
Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trialRoch Houot, Emmanuel Bachy, Guillaume Cartron, et al.
Pageof 15